Evaluation of standard chemotherapy in the guinea pig model of tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 1820-1833

  Ordway, Diane J ^a   Shanley, Crystal A ^a   Caraway, Megan L ^a   Orme, Eileen A ^a   Bucy, Daniel S ^a   Hascall Dove, Laurel ^a   Henao Tamayo, Marcela ^a   Harton, Marisa R ^a   Shang, Shaobin ^a   Ackart, David ^a   Kraft, Susan L ^a   Lenaerts, Anne J ^a   Basaraba, Randall J ^a   Orme, Ian M ^a  

^a Department of Environmental and Radiological Health Sciences   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; INTERLEUKIN 10; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; TRANSCRIPTION FACTOR FOXP3; TUBERCULOSTATIC AGENT;

ACID FAST BACTERIUM; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL VIRULENCE; CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; GUINEA PIG; LUNG CALCIFICATION; LUNG FIBROSIS; LUNG GRANULOMA; LUNG LESION; LUNG TUBERCULOSIS; LYMPHADENOPATHY; LYMPHANGITIS; LYMPHOCYTE; MICROSCOPY; MORNING DOSAGE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENOTYPE; POSTPRIMARY TUBERCULOSIS; PRIORITY JOURNAL; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; TH1 CELL;

ANIMALS; ANIMALS, OUTBRED STRAINS; ANTIGENS, CD45; ANTITUBERCULAR AGENTS; BIOLOGICAL MARKERS; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; DRUG THERAPY, COMBINATION; FEMALE; FLOW CYTOMETRY; FORKHEAD TRANSCRIPTION FACTORS; GUINEA PIGS; INTERLEUKIN-10; ISONIAZID; LUNG; LYMPH NODES; MAGNETIC RESONANCE IMAGING; PYRAZINAMIDE; RIFAMPIN; TH1 CELLS; TUBERCULOSIS, PULMONARY;

EID: 77951240110     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01521-09     Document Type: Article

References (46)

1. Allen, S. S., and D. N. McMurray. 2003. Coordinate cytokine gene expression in vivo following induction of tuberculous pleurisy in guinea pigs. Infect. Immun. 71:4271-4277.
2. Aziz, M. A., A. Wright, A. Laszlo, A. De Muynck, F. Portaels, A. Van Deun, C. Wells, P. Nunn, L. Blanc, and M. Raviglione. 2006. Epidemiology of antituberculosis drug resistance (the Global Project on Anti-Tuberculosis Drug Resistance Surveillance): an updated analysis. Lancet 368:2142-2154.
3. Basaraba, R. J. 2008. Experimental tuberculosis: the role of comparative pathology in the discovery of improved tuberculosis treatment strategies. Tuberculosis (Edinb.) 88(Suppl. 1):S35-S47.
4. Basaraba, R. J., D. D. Dailey, C. T. McFarland, C. A. Shanley, E. E. Smith, D. N. McMurray, and I. M. Orme. 2006. Lymphadenitis as a major element of disease in the guinea pig model of tuberculosis. Tuberculosis (Edinb.) 86:386-394.
5. Basaraba, R. J., A. A. Izzo, L. Brandt, and I. M. Orme. 2006. Decreased survival of guinea pigs infected with Mycobacterium tuberculosis after multiple BCG vaccinations. Vaccine 24:280-286.
6. Basaraba, R. J., E. E. Smith, C. A. Shanley, and I. M. Orme. 2006. Pulmonary lymphatics are primary sites of Mycobacterium tuberculosis infection in guinea pigs infected by aerosol. Infect. Immun. 74:5397-5401.
7. Basu, S., and A. P. Galvani. 2007. Extensively drug-resistant tuberculosis in South Africa. Lancet 369:272-273.
8. Bifani, P., B. Mathema, N. Kurepina, E. Shashkina, J. Bertout, A. S. Blanchis, S. Moghazeh, J. Driscoll, B. Gicquel, R. Frothingham, and B. N. Kreiswirth. 2008. The evolution of drug resistance in Mycobacterium tuberculosis: from a mono-rifampin-resistant cluster into increasingly multidrugresistant variants in an HIV-seropositive population. J. Infect. Dis. 198:90-94.
9. Botha, F. J., F. A. Sirgel, D. P. Parkin, B. W. van de Wal, P. R. Donald, and D. A. Mitchison. 1996. Early bactericidal activity of ethambutol, pyrazinamide and the fixed combination of isoniazid, rifampicin and pyrazinamide (Rifater) in patients with pulmonary tuberculosis. S. Afr. Med. J. 86:155-158.
10. Cho, H., T. M. Lasco, S. S. Allen, T. Yoshimura, and D. N. McMurray. 2005. Recombinant guinea pig tumor necrosis factor alpha stimulates the expression of interleukin-12 and the inhibition of Mycobacterium tuberculosis growth in macrophages. Infect. Immun. 73:1367-1376.
11. Cohen, T., C. Colijn, A. Wright, M. Zignol, A. Pym, and M. Murray. 2008. Challenges in estimating the total burden of drug-resistant tuberculosis. Am. J. Respir. Crit. Care Med. 177:1302-1306.
12. 18F]-2-fluorodeoxy-D-glucose positron emission tomography correlates with bactericidal activity of tuberculosis drug treatment. Antimicrob. Agents Chemother. 53:4879-4884.
13. Dye, C. 2006. Global epidemiology of tuberculosis. Lancet 367:938-940.
14. Dye, C., D. Maher, D. Weil, M. Espinal, and M. Raviglione. 2006. Targets for global tuberculosis control. Int. J. Tuber. Lung Dis. 10:460-462.
15. Dye, C., C. J. Watt, D. M. Bleed, S. M. Hosseini, and M. C. Raviglione. 2005. Evolution of tuberculosis control and prospects for reducing tuberculosis incidence, prevalence, and deaths globally. JAMA 293:2767-2775.
16. Espinal, M. A., and C. Dye. 2005 Can DOTS control multidrug-resistant tuberculosis? Lancet 365:1206-1209.
17. Gandhi, N. R., A. Moll, A. W. Sturm, R. Pawinski, T. Govender, U. Lalloo, K. Zeller, J. Andrews, and G. Friedland. 2006. Extensively drug-resistant tuberculosis as a cause of death in patients co-infected with tuberculosis and HIV in a rural area of South Africa. Lancet 368:1575-1580.
18. Ginsberg, A. M., and M. Spigelman. 2007. Challenges in tuberculosis drug research and development. Nat. Med. 13:290-294.
19. Githui, W. A. 2006. Multi drug resistant tuberculosis. East Afr. Med. J. 83:585-587.
20. Gomez, J. E., and J. D. McKinney. 2004. M. tuberculosis persistence, latency, and drug tolerance. Tuberculosis (Edinb.) 84:29-44.
21. Grosset, J. 1978. The sterilizing value of rifampicin and pyrazinamide in experimental short-course chemotherapy. Bull. Int. Union Tuberc. 53:5-12.
22. Harries, A. D., and C. Dye. 2006 Tuberculosis. Ann. Trop. Med. Parasitol. 100:415-431.
23. Hart, I. J., H. Schafer, R. J. Scheper, and G. T. Stevenson. 1992. Subpopulations of guinea-pig T lymphocytes defined by isoforms of the leucocyte common antigen. Immunology 77:377-384.
24. Haverson, K., M. Bailey, V. R. Higgins, P. W. Bland, and C. R. Stokes. 1994. Characterization of monoclonal antibodies specific for monocytes, macrophages and granulocytes from porcine peripheral blood and mucosal tissues. J. Immunol. Methods 170:233-245.
25. Hiromatsu, K., C. C. Dascher, M. Sugita, C. Gingrich-Baker, S. M. Behar, K. P. LeClair, M. B. Brenner, and S. A. Porcelli. 2002. Characterization of guinea-pig group 1 CD1 proteins. Immunology 106:159-172.
26. Hoff, D. R., M. L. Caraway, E. J. Brooks, E. R. Driver, G. J. Ryan, C. A. Peloquin, I. M. Orme, R. J. Basaraba, and A. J. Lenaerts. 2008. Metronidazole lacks antibacterial activity in guinea pigs infected with Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 52:4137-4140.
27. Kraal, G., R. Shiamatey-Koolma, M. Hoffer, D. Baker, and R. Scheper. 1988. Histochemical identification of guinea-pig macrophages by monoclonal antibody MR-1. Immunology 65:523-528.
28. Kraft, S. L., D. Dailey, M. Kovach, K. L. Stasiak, J. Bennett, C. T. Mc-Farland, D. N. McMurray, A. A. Izzo, I. M. Orme, and R. J. Basaraba. 2004. Magnetic resonance imaging of pulmonary lesions in guinea pigs infected with Mycobacterium tuberculosis. Infect. Immun. 72:5963-5971.
29. Lenaerts, A. J., P. L. Chapman, and I. M. Orme. 2004. Statistical limitations to the Cornell model of latent tuberculosis infection for the study of relapse rates. Tuberculosis (Edinb.) 84:361-364.
30. Lenaerts, A. J., M. A. Degroote, and I. M. Orme. 2008. Preclinical testing of new drugs for tuberculosis: current challenges. Trends Microbiol. 16:48-54.
31. Lenaerts, A. J., D. Hoff, S. Aly, S. Ehlers, K. Andries, L. Cantarero, I. M. Orme, and R. J. Basaraba. 2007. Location of persisting mycobacteria in a guinea pig model of tuberculosis revealed by r207910. Antimicrob. Agents Chemother. 51:3338-3345.
32. McMurray, D. N. 2001. Disease model: pulmonary tuberculosis. Trends Mol. Med. 7:135-137.
33. McMurray, D. N., S. S. Allen, A. Jeevan, T. Lasco, H. Cho, T. Skwor, T. Yamamoto, C. McFarland, and T. Yoshimura. 2005. Vaccine-induced cytokine responses in a guinea pig model of pulmonary tuberculosis. Tuberculosis (Edinb.) 85:295-301.
34. Mendez, S., R. Traslavina, M. Hinchman, L. Huang, P. Green, M. H. Cynamon, and J. T. Welch. 2009. The antituberculosis drug pyrazinamide affects the course of cutaneous leishmaniasis in vivo and increases activation of macrophages and dendritic cells. Antimicrob. Agents Chemother. 53:5114-5121.
35. Mitchison, D. A. 1996. Pyrazinamide - on the antituberculosis drug frontline. Nat. Med. 2:635-636.
36. Mitsuyama, M., and D. N. McMurray. 2007. Tuberculosis: vaccine and drug development. Tuberculosis (Edinb.) 87(Suppl. 1):S10-S13.
37. Ojha, A. K., A. D. Baughn, D. Sambandan, T. Hsu, X. Trivelli, Y. Guerardel, A. Alahari, L. Kremer, W. R. Jacobs, Jr., and G. F. Hatfull. 2008. Growth of Mycobacterium tuberculosis biofilms containing free mycolic acids and harbouring drug-tolerant bacteria. Mol. Microbiol. 69:164-174.
38. Ordway, D., M. Henao-Tamayo, M. Harton, G. Palanisamy, J. Troudt, C. Shanley, R. J. Basaraba, and I. M. Orme. 2007. The hypervirulent Mycobacterium tuberculosis strain HN878 induces a potent TH1 response followed by rapid down-regulation. J. Immunol. 179:522-531.
39. Ordway, D., M. Henao-Tamayo, C. Shanley, E. E. Smith, G. Palanisamy, B. Wang, R. J. Basaraba, and I. M. Orme. 2008. Influence of Mycobacterium bovis BCG vaccination on cellular immune response of guinea pigs challenged with Mycobacterium tuberculosis. Clin. Vaccine Immunol. 15:1248-1258.
40. Ordway, D., G. Palanisamy, M. Henao-Tamayo, E. E. Smith, C. Shanley, I. M. Orme, and R. J. Basaraba. 2007. The cellular immune response to Mycobacterium tuberculosis infection in the guinea pig. J. Immunol. 179:2532-2541.
41. Palanisamy, G. S., N. DuTeau, K. D. Eisenach, D. M. Cave, S. A. Theus, B. N. Kreiswirth, R. J. Basaraba, and I. M. Orme. 2009. Clinical strains of Mycobacterium tuberculosis display a wide range of virulence in guinea pigs. Tuberculosis (Edinb.) 89:203-209.
42. Spigelman, M., and S. Gillespie. 2006. Tuberculosis drug development pipeline: progress and hope. Lancet 367:945-947.
43. Spigelman, M. K. 2007. New tuberculosis therapeutics: a growing pipeline. J. Infect. Dis. 196(Suppl. 1):S28-S34.
44. Takizawa, M., J. Chiba, S. Haga, T. Asano, T. Yamazaki, N. Yamamoto, and M. Honda. 2006. Novel two-parameter flow cytometry (MIL4/SSC followed by MIL4/CT7) allows for identification of five fractions of guinea pig leukocytes in peripheral blood and lymphoid organs. J. Immunol. Methods 311:47-56.
45. Tan, B. T., F. Ekelaar, J. Luirink, G. Rimmelzwaan, A. J. De Jonge, and R. J. Scheper. 1985. Production of monoclonal antibodies defining guinea pig T-cell surface markers and a strain 13 Ia-like antigen: the value of immunohistological screening. Hybridoma 4:115-124.
46. Wilcox, C. E., D. Baker, C. Butter, D. A. Willoughby, and J. L. Turk. 1989. Differential expression of guinea pig class II major histocompatibility complex antigens on vascular endothelial cells in vitro and in experimental allergic encephalomyelitis. Cell. Immunol. 120:82-91.